Autoantibodies to kininogen-phosphatidylethanolamine complexes augment thrombin-induced platelet aggregation

Thrombosis Research

Volumn 84, Issue 2, 1996, Pages 97-109

  Sugi, Toshitaka ^a   McIntyre, John A ^b  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b METHODIST HOSPITAL   (United States)

Author keywords

autoantibodies; kininogen; phosphatidylethanolamine; platelet aggregation; thrombin

Indexed keywords

AUTOANTIBODY; KININOGEN; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLETHANOLAMINE ANTIBODY; THROMBIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

EID: 0030588260     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/0049-3848(96)00165-X     Document Type: Article

References (53)

1. McNEIL H.P., Chesterman C.N., Krilis S.A. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol. 49:1991;193-280.
2. HUGHES G.R.V., Harris E.N., Gharavi A.E. The anticardiolipin syndrome. J Reumatol. 18:1986;486-489.
3. LOVE P.E., Santoro S.A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med. 112:1990;682-698.
4. TRIPLETT, D.A. Obstetrical complications associated with antiphospholipid antibodies. In Immunological Obstetrics, C.B. Coulam, W.P. Faulk, J.A. McIntyre, (eds), pp 377-403, W.W. Norton, New York, 1992.
5. STAUB H.L., Harris E.N., Khamashta M.H., Savidge G., Chahade W.H., Hughes G.R.V. Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis. Ann Rheum Dis. 48:1989;166-169.
6. KARMOCHKINE M., Cacoub P., Piette J.C., Godear P., Boffa M.C. Antiphosphatidylethanolamine antibody as the sole antiphospholipid antibody in systemic lupus erythematosus with thrombosis. Clin Exp Rheumatol. 10:1992;603-605.
7. KARMOCHKINE M., Berard M., Piette J.C., Cacoub P., Ailland M.F., Harlet J.R., Godeau P., Boffa M.C. Antiphosphatidylethanolamine antibodies in systemic lupus erythematosus. Lupus. 2:1993;157-160.
8. BOFFA M.C., Berak M., Sugi T., McIntyre J.A. Kininogen reactivity of antiphosphatidylethanolamine antibodies found as the sole antiphospholipid antibodies in thrombosis and vascular cutaneous disease. J Rheumatol. 23:1996;1375-1379.
9. McNEIL H.P., Simpson R.J., Chesterman C.N., Krilis S.A. Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA. 87:1990;4120-4124.
10. GALLI M., Comfurius P., Massen C., Hemker H.C., De Baets M.H., van BredaVriesman P.J.C., Barbui T., Zwaal R.F.A., Bevers E.M. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet. 335:1990;1544-1547.
11. FLECK R.A., Rapaport S.I., Rao L.V. Anti-prothrombin antibodies and the lupus anticoagulant. Blood. 72:1988;512-519.
12. BEVERS E.M., Galli M., Barbui T., Comfurius P., Zwaal RFA Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin. Thromb Haemost. 66:1991;629-632.
13. OOSTING J.D., Derksen R.H.W.M., Bobbink I.W.G., Hackeng T.M., Bouma B.N., De Groot P.G. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood. 81:1993;2618-2625.
14. ROUBEY R. Autoantibodies to phospholipid-binding plasma proteins: A new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood. 84:1994;2854-2867.
15. SUGI T., McIntyre J.A. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood. 86:1995;3083-3089.
16. OHKUBO I., Namikawa C., Higashiyama S., Sasaki M., Minowa O., Minuzo Y., Shiokawa H. Purification and characterization of α1-thiol proteinase inhibitor and its identity with kinin and fragment 1,2 free high molecular weight kininogen. Int J Biochem. 20:1988;243-251.
17. GUSTAFSON E.J., Schutsky D., Knight L.C., Schmaier A.H. High molecular weight kininogen binds to unstimulated platelets. J Clin Invest. 78:1986;310-318.
18. IWAARDEN F.V., de Groot P.G., Bouma B.N. The binding of high molecular weight kininogen to cultured human endothelial cells. J Biol Chem. 263:1988;4693-703.
19. GUSTAFSON E.J., Schmaier A.H., Wachtfogel Y.T., Kaufman N., Kucich U., Colman R.W. Human neutrophils contain and bind high molecular weight kininogen. J Clin Invest. 84:1989;28-35.
20. PURI R.N., Zhou F., Hu C.J., Colman R.F., Colman R.W. High molecular weight kininogen inhibits thrombin-induced platelet aggregation and cleavage of aggregin by inhibiting binding of thrombin to platelets. Blood. 77:1991;500-507.
21. DeLa CADENA R.A., Colman R.W. Structure and functions of human kininogens. Tips. 12:1991;272-275.
22. KUNAPULI S.P., Colman R.W. Platelet-kininogen interaction. Platelets. 4:1993;61-65.
23. DeLa CADENA R.A., Wyshock E.G., Walz D.A., Colman R.W. Structural determinants of the binding of human high molecular weight kininogen (HK) to platelet thrombospondin (TSP). Thromb Haemost. 65:1992;699.
24. DeLa CADENA R.A., Bradford H.N., Kunapuli S.P., Colman R.W. The platelet binding site on the heavy chains of human high (HK) and low (LK) molecular weight kininogens is confined to residues Lys-262-Pro-272. Blood. 82:1993;77a.
25. BEVERS E.M., Comfurius P., Zwaal R.F.A. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta. 736:1983;57-66.
26. SUGI, T. and McIntyre, J.A. Plasma proteins required for antiphospholipid antibody detection. Nouv Rev Fr Hematol 37, S49-52, 1995.
27. JOHNSON D.A., Salvesen G., Brown M.A., Barrett A.J. Rapid isolation of human kininogens. Thromb Res. 48:1987;187-193.
28. SUGI T., McIntyre J.A. Phosphatidylethanolamine induces specific conformational changes in the kininogens recognizable by antiphosphatidylethanolamine antibodies. Thromb Haemost. 76(3):1996;354-360.
29. WAGENKNECHT D.R., Sugi T., McIntyre J.A. The evolution, evaluation and interpretation of antiphospholipid antibody assays. Clin Immunol Newsletter. 15:1995;28-38.
30. MICHELSON A.D., MacGregor H., Barnard M.R., Kestin A.S., Rohrer M.J., Valeri C.R. Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thromb Haemost. 71:1994;633-640.
31. CAMPBELL A.L., Pierangeli S.S., Wellhausen S., Harris E.N. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost. 73:1995;529-534.
32. LELLOUCHE F., Martinuzzo M., Said P., Maclouf J., Carreras L.O. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood. 78:1991;2894-2899.
33. MARTINUZZO M.E., Maclouf J., Carreras L.O., Levy-Toledano S. Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost. 70:1993;667-671.
34. COLMAN R.W. Aggregin: A platelet ADP receptor that mediates activation. FASEB J. 4:1990;1425-1435.
35. FIGURES W.R., Niewiarowski S., Morinelli T.A., Colman R.F., Colman R.W. Affinity labeling of a human platelet membrane protein with 5′-p-flurosulfonylbenzoyl adenosine. J Biol Chem. 256:1981;7789-7795.
36. 2-adrenoreceptor interaction: Evidence for an ADP requirement for epinephrine-induced platelet activation and an influence of epinephrine on ADP binding. J Biol Chem. 261:1986;5981-5986.
37. COLMAN R.W., Figures W.F., Scearce L.M., Strimpler A.M., Zhou F., Rao A.K. Inhibition of collagen-induced platelet activation by 5′-p-fluorosulfonylbenzoyl adenosine: Evidence for an ADP requirement and synergistic influence of prostaglandin endoperoxides. Blood. 68:1986;565-570.
38. MORINELLI T.A., Niewiarowski S., Kornecki E., Figures W.R., Wachtfogel Y., Colman R.W. Platelet aggregation and exposure of fibrinogen receptors by prostaglandin endoperoxide analogues. Blood. 61:1983;41-49.
39. PURI R.N., Zhou F., Colman R.F., Colman R.W. Cleavage of a 100 kD membrane protein (aggregin) during thrombin-induced platelet aggregation is mediated by high affinity thrombin receptors. Biochem Biophys Res Commun. 162:1989;1017-1024.
40. PURI R.N., Zhou F., Bradford H.N., Hu C-J., Colman R.F., Colman R.W. Thrombin-induced platelet aggregation involves an indirect proteolytic cleavage of a 100 kD membrane protein. Arch Biochem Biophys. 271:1989;346-358.
41. OHKUBO I., Kurachi K., Takasawa T., Shiokawa H., Sasaki M. Isolation of a human cDNA for alpha 2-thiol proteinase inhibitor and its identity with low molecular weight kininogen. Biochemistry. 23:1984;5691-5697.
42. MELONI F.J., Schmaier A.H. Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. J Biol Chem. 266:1991;6786-6794.
43. SCHMAIER A.H., Smith P.M., Purdon A.D., White J.G., Colman R.W. High molecular weight kininogen: localization in the unstimulated and activated platelet and activation by a platelet calpain(s). Blood. 67:1986;119-130.
44. SCHMAIER A.H., Bradford H., Silver L.D., Farver A., Scott C.F., Schutsky D., Colman R.W. High molecular weight kininogen is an inhibitor of platelet calpain. J Clin Invest. 77:1986;1565-1573.
45. MULLER-ESTEL W., Fritz H., Machleidt W., Ritonja A., Brzin J., Kotnik M., Turk V., Kellerman J., Lottspeich F. Human plasma kininogens are identical with alpha-cysteine proteinase inhibitors: Evidence from immunological, enzymological and sequence data. FEBS Lett. 182:1985;310-314.
46. SALVESEN G., Parkes C., Abrahamson M., Grubb A., Barrett A.J. Human low-MR kininogen contains three copies of a cystatin sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. Biochem J. 234:1986;429-434.
47. SCHMAIER A.H., Bradford H.N., Lundberg D., Farber A., Colman R.W. Membrane expression of platelet calpain. Blood. 75:1990;1273-1281.
48. PURI, R.N., Zhou, F.X., Colman, R.F. and Colman, R.W. Plasmin-induced platelet aggregation is accompanied by cleavage of aggregin and indirectly mediated by calpain. Am J Physiol 259, C862-868, 1990.
49. PURI R.N., Matsueda R., Umeyama H., Bradford H.N., Colman R.W. Modulation of thrombin-induced platelet aggregation by inhibition of calpain by a synthetic peptide derived from the thiol-protease inhibitory sequence of kininogens and S-(3-nitro-2-pyridinesulfenyl)-cysteine. Eur J Biochem. 214:1993;233-241.
50. JIANG Y.P., Muller Estel W., Schmaier A.H. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets. J Biol Chem. 267:1992;3712-3717.
51. HANSEN S.R., Harker L. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin PPACK. Proc Natl Acad Sci USA. 85:1988;3184-3188.
52. EIDT J.F., Allison P., Nobel S., Ashton J., Golino P., McNatt J., Buja L.M., Willerson J. Thrombin is an important mediator of platelet aggregation in stenosed coronary arteries. J Clin Invest. 84:1989;18-27.
53. KELLY A.B., Marzec U.M., Krupski W., Bass A., Cardroy Y., Hanson S.R., Harker L.A. Hiruidin interruption of heparin-resistant arterial thrombosis formation in baboons. Blood. 66:1991;1006-1012.